Literature DB >> 11675360

The AKT kinase is activated in multiple myeloma tumor cells.

J Hsu1, Y Shi, S Krajewski, S Renner, M Fisher, J C Reed, T F Franke, A Lichtenstein.   

Abstract

Immunohistochemistry (IHC) was performed on archived bone marrow (BM) with a phosphospecific anti-AKT antibody. IHC on 26 BM biopsies from patients with multiple myeloma (MM) demonstrated phospho-AKT staining of malignant plasma cells in a cell membrane-specific pattern, whereas nonmalignant hematopoietic cells did not stain. Preabsorption of the antibody with phosphorylated AKT peptide, but not nonphosphorylated peptide, abrogated staining. Frequency of plasma cell staining in BMs of patients with stage I or smoldering MM was significantly less than that of stage III MM marrows. Plasma cells in 10 patients with monoclonal gammopathy of undetermined significance were not stained by the antibody. To investigate the significance of AKT activation, 2 cell lines initiated from cultures of primary MM cells were also studied. Both demonstrated constitutive AKT activation. Interruption of AKT activation and activity, achieved by either exposure to wortmannin or by ectopic expression of a dominant negative AKT mutant, resulted in inhibition of MM cell growth in vitro. These results indicate that activation of the AKT kinase is a characteristic of MM cells and suggest that AKT activity is important for MM cell expansion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11675360     DOI: 10.1182/blood.v98.9.2853

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

Review 1.  Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology.

Authors:  James W Mandell
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

2.  Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.

Authors:  Diana Cirstea; Teru Hideshima; Scott Rodig; Loredana Santo; Samantha Pozzi; Sonia Vallet; Hiroshi Ikeda; Giulia Perrone; Gullu Gorgun; Kishan Patel; Neil Desai; Peter Sportelli; Shweta Kapoor; Shireen Vali; Siddhartha Mukherjee; Nikhil C Munshi; Kenneth C Anderson; Noopur Raje
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

Review 3.  Mammalian target of rapamycin as a target in hematological malignancies.

Authors:  Kevin R Kelly; Julie H Rowe; Swaminathan Padmanabhan; Steffan T Nawrocki; Jennifer S Carew
Journal:  Target Oncol       Date:  2011-04-17       Impact factor: 4.493

4.  Frequent activation of mitogen-activated protein kinase relative to Akt in extrahepatic biliary tract cancer.

Authors:  Hiroshige Hori; Tetsuo Ajiki; Yoshiyasu Mita; Hideki Horiuchi; Kenro Hirata; Taku Matsumoto; Haruki Morimoto; Tsunenori Fujita; Yonson Ku; Yoshikazu Kuroda
Journal:  J Gastroenterol       Date:  2007-07-25       Impact factor: 7.527

5.  Bufalin Enhances the Cytotoxity of Human Multiple Myeloma Cells H929 to AKT Inhibitor MK2206: The Role of Protein AKT Phosphorylation.

Authors:  He Huang; Xiao-Ji Lin; Ying Lin; Ron-Xin Yao; Mu-Qing He
Journal:  Indian J Hematol Blood Transfus       Date:  2017-09-30       Impact factor: 0.900

6.  Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

Authors:  Teru Hideshima; Laurence Catley; Hiroshi Yasui; Kenji Ishitsuka; Noopur Raje; Constantine Mitsiades; Klaus Podar; Nikhil C Munshi; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

Review 7.  Multistep tumorigenesis of multiple myeloma: its molecular delineation.

Authors:  Shinsuke Iida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

8.  Deguelin, a natural rotenoid, inhibits mouse myeloma cell growth in vitro via induction of apoptosis.

Authors:  Zhengguang Li; Jun Wu; Changping Wu; Jingting Jiang; Xiao Zheng; Bin Xu; Min Li
Journal:  Oncol Lett       Date:  2012-07-06       Impact factor: 2.967

9.  Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling.

Authors:  Oak D Jo; Jheralyn Martin; Andrew Bernath; Janine Masri; Alan Lichtenstein; Joseph Gera
Journal:  J Biol Chem       Date:  2008-06-18       Impact factor: 5.157

10.  Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.

Authors:  Naoya Mimura; Teru Hideshima; Toshiyasu Shimomura; Rikio Suzuki; Hiroto Ohguchi; Ola Rizq; Shohei Kikuchi; Yasuhiro Yoshida; Francesca Cottini; Jana Jakubikova; Diana Cirstea; Gullu Gorgun; Jiro Minami; Yu-Tzu Tai; Paul G Richardson; Teruhiro Utsugi; Atsushi Iwama; Kenneth C Anderson
Journal:  Cancer Res       Date:  2014-06-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.